Adiponectin and Coronary Heart Disease: The Strong Heart Study

Lindsay, Robert; Resnick, Helaine E.; Zhu, Jianhui; Tun, Min L.; Howard, Barbara V.; Zhang, Ying; Yeh, Jeunliang; Best, Lyle G.

doi:10.1161/01.atv.0000153090.21990.8c

Cited by 153 publications

(112 citation statements)

References 18 publications

Supporting

Mentioning

101

Contrasting

Unclassified

Order By: Relevance

“…Of the classical CHD risk factors, adiponectin did not associate with systolic blood pressure, cholesterol or fibrinogen, suggesting that adiponectin may play a more important role in insulin resistance and the development of diabetes. In line with this possibility, no significant association was seen between adiponectin and prevalent vascular disease, which is consistent with recent prospective case-control studies showing no association between adiponectin and CHD 20,22 and at variance with the first reported prospective study. 19 Adiponectin was strongly associated with obesity, but was associated with few other lifestyle characteristics associated with CHD or diabetes.…”

Section: Discussionsupporting

confidence: 91%

“…[11][12][13][14][15][16] Although an inverse association has been found between adiponectin and prevalent coronary heart disease (CHD) in crosssectional studies, 17,18 prospective studies have produced conflicting results. [19][20][21][22] It remains uncertain whether adiponectin is a critical factor in the 'common soil' 23 leading to both diabetes and cardiovascular disease.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Associations of adiponectin with metabolic and vascular risk parameters in the British Regional Heart Study reveal stronger links to insulin resistance-related than to coronory heart disease risk-related parameters

et al. 2007

View full text Add to dashboard Cite

Background and aim: Adiponectin is considered by many to be part of the 'common soil' linking type 2 diabetes and coronary heart disease (CHD). We examined the relationship between adiponectin and insulin resistance, metabolic, inflammatory and haemostatic risk factors and hepatic function. Methods and results: The study was carried out in 3640 non-diabetic men aged 60-79 years drawn from general practices in 24 British towns and who were not on warfarin. Adiponectin was associated with waist circumference (inversely), alcohol intake (positively) and physical activity (nonlinearly); no association was seen with cigarette smoking, prevalent CHD or stroke. After adjustment for these factors, adiponectin was significantly inversely associated with insulin resistance, triglyceride, C-reactive protein (but not interleukin 6), tissue plasminogen activator and alanine aminotransferase and positively associated with highdensity lipoprotein cholesterol (HDL-cholesterol) and Factor VIII, factors associated with diabetes. No association was seen with cholesterol, smoking, systolic blood pressure or coagulation factors. Risk of the metabolic syndrome decreased significantly with increasing adiponectin. Conclusion: Adiponectin is inversely associated with factors strongly associated with the development of diabetes. Limited associations with the established major risk factors for CHD suggest adiponectin may be a stronger marker of risk for diabetes than for CHD.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Introductionmentioning

confidence: 99%

Associations of adiponectin with metabolic and vascular risk parameters in the British Regional Heart Study reveal stronger links to insulin resistance-related than to coronory heart disease risk-related parameters

et al. 2007

View full text Add to dashboard Cite

show abstract

“…23-25 Some but not all prospective studies of healthy individuals have reported that higher adiponectin levels are associated with decreased risk of incident myocardial infarction in men and women. [26][27][28][29] In contrast, a recent prospective study reported that higher adiponectin levels are associated with greater cardiovascular mortality in men. 29 Further research is needed to evaluate the relationship between adiponectin levels and cardiovascular outcomes in hypogonadal men.…”

Section: Commentmentioning

confidence: 94%

Adipocytokines, Obesity, and Insulin Resistance During Combined Androgen Blockade for Prostate Cancer

Smith¹,

Lee²,

Fallon³

et al. 2008

Urology

110

View full text Add to dashboard Cite

Objectives-Gonadotropin-releasing hormone agonists increase fat mass, decrease insulin sensitivity, and increase serum triglycerides-changes suggestive of the classic metabolic syndrome. These analyses were designed to assess the effects of gonadotropin-releasing hormone agonist treatment on other markers of the metabolic syndrome including adiponectin, resistin, and plasminogen activator inhibitor type 1 (PAI-1) levels and to evaluate relationships between changes in adipocytokines, body composition, and insulin sensitivity.Methods-In this prospective 12-week study, 25 nondiabetic men with locally advanced or recurrent prostate cancer and no radiographic evidence of metastases were treated with leuprolide depot and bicalutamide. Outcomes included changes from baseline to week 12 in body composition, insulin sensitivity, and levels of adiponectin, resistin, and PAI-1.Results-Mean (± SE) percentage fat body mass increased by 4.3 ± 1.3% from baseline to week 12 (P=0.002). Insulin sensitivity index decreased by 12.9 ± 7.6% (P=0.02). Serum adiponectin levels increased by 37.4 ± 7.2% from baseline to week 12 (P<0.001). In contrast, serum resistin levels did not change significantly. Changes in adiponectin were associated with changes lean mass (r=0.448; P=0.02) and fat mass (r=−0.383; P=0.06) but not changes in insulin sensitivity.Conclusions-Combined androgen blockade with leuprolide and bicalutamide significantly increased serum adiponectin levels but did not alter PAI-1 or resistin levels. This pattern of metabolic changes appears distinct from the classic metabolic syndrome.

show abstract

“…10 Beyond the cross-sectional data on adiponection and CHD, results of prospective studies have been conflicting so far. [11][12][13][14] Whereas in men aged 40-75 years (US Health Professionals Follow-up Study) high adiponectin concentrations were related to a lower risk of myocardial infarction both in all subjects and in type 2 diabetic patients, 12,13 no associations were found in American Indians, 11 and in elderly women aged 60-79 years from the British Women's Heart and Health Study. 14 Conflicting results have also been published for adiponectin and stroke.…”

Section: Introductionmentioning

confidence: 99%

Differential association of adiponectin with cardiovascular risk markers in men and women? The KORA survey 2000

et al. 2006

View full text Add to dashboard Cite

Background: In men, high adiponectin concentrations were related to a lower risk of myocardial infarction, whereas no association with cardiovascular events was found in women. Objective: To investigate sex differences in the associations of adiponectin with cardiovascular risk factors. Design: Cross-sectional population-based KORA Survey 2000 in Southern Germany using the same study methods for cardiovascular risk factors as the former WHO MONICA project. Participants: A total of 697 men and 657 women, aged 55-74 years. Glucose tolerance status was assessed by oral glucose tolerance tests. Results: Adiponectin (geometric mean, interquartile range; mg/ml) levels were significantly higher in women (11.1; 8.5-14.9) than in men (7.1; 5.2-9.6) (Po0.05). In univariate analyses, HDL-cholesterol and age were significantly positively correlated with adiponectin in both sexes. Negative correlations were observed with BMI, waist circumference, fasting and postchallenge glucose, insulin, HOMA-IR, HbA1c, triglycerides, uric acid and CRP (Po0.01). In sex-specific multivariate regression, age and HDL-cholesterol were independently positively, and fasting insulin and 2-h glucose were negatively related to adiponectin in both sexes. Uric acid was significantly inversely related to adiponectin in women only (sex interaction: P ¼ 0.02). Exploratory sex-specific factor analysis of adiponectin and the core components of the metabolic syndrome yielded four similar factors. Adiponectin loaded negatively on the 'lipids' factor in both sexes. Conclusion: The associations of adiponectin with cardiovascular risk factors showed a similar pattern in both sexes, except for uric acid. This small sex difference may not explain previous conflicting results on the association of adiponectin with cardiovascular events in men and women.

show abstract

Adiponectin and Coronary Heart Disease: The Strong Heart Study

Cited by 153 publications

References 18 publications

Associations of adiponectin with metabolic and vascular risk parameters in the British Regional Heart Study reveal stronger links to insulin resistance-related than to coronory heart disease risk-related parameters

Associations of adiponectin with metabolic and vascular risk parameters in the British Regional Heart Study reveal stronger links to insulin resistance-related than to coronory heart disease risk-related parameters

Adipocytokines, Obesity, and Insulin Resistance During Combined Androgen Blockade for Prostate Cancer

Differential association of adiponectin with cardiovascular risk markers in men and women? The KORA survey 2000

Contact Info

Product

Resources

About